Document is current

Article History

Received: 16 July 2024

Accepted: 30 August 2024

First Online: 30 September 2024

Declarations

:

: Tim Snel, Helena Koenig. and Sven Reinhardt, have a paid position at Roche Diabetes Care, a company that markets tools related to diabetes self-management. Guido Freckmann is general manager and medical director of the Institute for Diabetes Technology (Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany), which carries out clinical studies for example with medical devices for diabetes therapy on its own initiative and on behalf of various companies. G.F./IfDT have received research support, speakers’ honoraria, or consulting fees in the last 3 years from Abbott, Ascensia, Berlin Chemie, BOYDSense, Dexcom, Lilly, Novo Nordisk, Perfood, Pharmasens, Roche, Sinocare, Terumo, Ypsomed. Stefan Pleus is an employee of IDT.

: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Landesärztekammer Baden-Württemberg (protocol code DC000058, EU-DAMED-Nr.: CIV-20–01-031566) on 20-Apr-2020. Informed consent was obtained from all subjects involved in the study.